These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23833185)

  • 1. Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.
    Fofana DB; Soulie C; Maiga AI; Fourati S; Malet I; Wirden M; Tounkara A; Traore HA; Calvez V; Marcelin AG; Lambert-Niclot S
    J Antimicrob Chemother; 2013 Nov; 68(11):2515-20. PubMed ID: 23833185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
    Fofana DB; Charpentier C; Maïga AI; Lambert-Niclot S; Sayon S; Désiré N; Simon A; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG; Soulié C
    J Antimicrob Chemother; 2015 Jan; 70(1):130-5. PubMed ID: 25270328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
    Anta L; Blanco JL; Llibre JM; García F; Pérez-Elías MJ; Aguilera A; Pérez-Romero P; Caballero E; Vidal C; Cañizares A; Gutiérrez F; Dalmau D; Iribarren JA; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2013 Sep; 68(9):1994-2002. PubMed ID: 23629015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana DB; Soulié C; Fourati S; Visseaux B; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1237-42. PubMed ID: 23361642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
    Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
    Maïga AI; Malet I; Soulie C; Derache A; Koita V; Amellal B; Tchertanov L; Delelis O; Morand-Joubert L; Mouscadet JF; Murphy R; Cissé M; Katlama C; Calvez V; Marcelin AG
    Antivir Ther; 2009; 14(1):123-9. PubMed ID: 19320246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
    Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
    J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana D; Soulie C; Fourati S; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2014 Apr; 69(4):1086-9. PubMed ID: 24302653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
    Crawford KW
    AIDS; 2014 Sep; 28(15):2331-2. PubMed ID: 25050862
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
    Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
    Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
    van de Vijver DA; Wensing AM; Angarano G; Asjö B; Balotta C; Boeri E; Camacho R; Chaix ML; Costagliola D; De Luca A; Derdelinckx I; Grossman Z; Hamouda O; Hatzakis A; Hemmer R; Hoepelman A; Horban A; Korn K; Kücherer C; Leitner T; Loveday C; MacRae E; Maljkovic I; de Mendoza C; Meyer L; Nielsen C; Op de Coul EL; Ormaasen V; Paraskevis D; Perrin L; Puchhammer-Stöckl E; Ruiz L; Salminen M; Schmit JC; Schneider F; Schuurman R; Soriano V; Stanczak G; Stanojevic M; Vandamme AM; Van Laethem K; Violin M; Wilbe K; Yerly S; Zazzi M; Boucher CA
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):352-60. PubMed ID: 16540937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
    Maïga AI; Descamps D; Morand-Joubert L; Malet I; Derache A; Cisse M; Koita V; Akonde A; Diarra B; Wirden M; Tounkara A; Verlinden Y; Katlama C; Costagliola D; Masquelier B; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2010 Feb; 54(2):728-33. PubMed ID: 20008779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
    Asahchop EL; Wainberg MA; Oliveira M; Xu H; Brenner BG; Moisi D; Ibanescu IR; Tremblay C
    AIDS; 2013 Mar; 27(6):879-887. PubMed ID: 23262501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy.
    Crawford KW; Njeru D; Maswai J; Omondi M; Apollo D; Kimetto J; Gitonga L; Munyao J; Langat R; Aoko A; Tarus J; Khamadi S; Hamm TE
    AIDS; 2014 Jan; 28(3):442-5. PubMed ID: 24670527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.
    Saravanan S; Kausalya B; Gomathi S; Sivamalar S; Pachamuthu B; Selvamuthu P; Pradeep A; Sunil S; Mothi SN; Smith DM; Kantor R
    AIDS Res Hum Retroviruses; 2017 Jun; 33(6):567-574. PubMed ID: 27869478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
    Pereira-Vaz J; Duque V; Pereira B; Mota V; Morais C; Saraiva-da-Cunha J; Meliço-Silvestre A
    J Med Virol; 2012 Apr; 84(4):551-4. PubMed ID: 22337292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.
    Asahchop EL; Oliveira M; Wainberg MA; Brenner BG; Moisi D; Toni Td; Tremblay CL
    Antimicrob Agents Chemother; 2011 Feb; 55(2):600-7. PubMed ID: 21135184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.
    Turner D; Shahar E; Katchman E; Kedem E; Matus N; Katzir M; Hassoun G; Pollack S; Kessner R; Wainberg MA; Avidor B
    J Med Virol; 2009 Sep; 81(9):1509-12. PubMed ID: 19626612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.